Lexaria Extends Partnership With PharmaCO To April 2026 For Ongoing Evaluation Of DehydraTECH, Following Australian Study Data Review

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally entered into on September 4, 2024 with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECHTM technology in a pre-clinical setting.

The original agreement has been extended through April 30, 2026, to accommodate time needed for PharmaCO's receipt and review of the full dataset from Lexaria's Australian study, at which time further information will be provided. This allows the two parties to continue their relationship under the MTA, keep the temporary exclusive license active and in force, and contemplate additional strategic planning discussions with PharmaCO's human clinical development team.

Earlier in 2025, initial pre-clinical studies covered by the MTA, which examined pharmacokinetics in animals, had been completed. At that time, Lexaria had been informed by PharmaCO that they wished to review the pending safety (adverse events), pharmacokinetic and efficacy data from Lexaria's independent, Australian human clinical study GLP-1-H24-4, which is currently at the stage of full sample and data analyses as previously announced. Lexaria expects to release the final results of the Australian study when available, which is currently projected to be before the end of the fourth quarter of calendar 2025.